Guggenheim Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC)

Guggenheim reissued their buy rating on shares of Century Therapeutics (NASDAQ:IPSC) in a research report report published on Wednesday,Benzinga reports.

Other equities analysts have also issued research reports about the stock. Chardan Capital decreased their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a report on Wednesday. Finally, Piper Sandler dropped their target price on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a report on Monday, December 30th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Century Therapeutics presently has an average rating of “Buy” and an average target price of $10.00.

Century Therapeutics Trading Down 1.1 %

IPSC opened at $0.90 on Wednesday. The business’s 50 day moving average is $1.17 and its 200-day moving average is $1.55. The stock has a market cap of $76.53 million, a PE ratio of -0.49 and a beta of 1.76. Century Therapeutics has a twelve month low of $0.86 and a twelve month high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last announced its earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The firm had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.47 million. During the same quarter in the previous year, the business earned ($0.55) EPS. As a group, analysts forecast that Century Therapeutics will post -1.63 EPS for the current year.

Institutional Trading of Century Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in Century Therapeutics by 257.6% in the third quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock worth $123,000 after buying an additional 51,664 shares during the last quarter. Barclays PLC grew its holdings in shares of Century Therapeutics by 283.6% in the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after acquiring an additional 45,797 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Century Therapeutics by 3.5% during the third quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock worth $1,656,000 after purchasing an additional 32,614 shares during the period. Wellington Management Group LLP purchased a new stake in shares of Century Therapeutics during the third quarter valued at $284,000. Finally, State Street Corp boosted its position in shares of Century Therapeutics by 7.4% in the 3rd quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after purchasing an additional 57,323 shares during the period. 50.20% of the stock is currently owned by institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.